ENDP - Endo epilepsy therapy cenobamate gets Health Canada review

• Health Canada accepted to review a new drug submission (NDS) by Paladin Labs, a unit of Endo International ( NASDAQ: ENDP ), seeking approval of cenobamate as an adjunctive therapy to manage partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
• SK Biopharmaceuticals said that in December 2021 it signed agreements with Endo to commercialize cenobamate in Canada.
• SK added that its partner, Dexcel Pharma's application for cenobamate was also accepted for review by the Israel Ministry of Health.
• SK noted that it is eligible to receive milestones for future approval and commercialization in Canada and Israel.
• Earlier in the day, Endo reported its Q2 results and noted that a Chapter 11 bankruptcy filing could occur imminently.

For further details see: